secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2026-06-12T20:11:14+00:00
Accession:  0001193125-26-269431
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio stockholders approve amended 2021 equity plan and elect two Class II directors
--------------------------------------------------------------------------------

- Andrew Levin, M.D., Ph.D. elected with 25,797,081 for, 120,813 withheld; Fouad Namouni, M.D. elected with 22,825,938 for, 4,091,956 withheld.
- Amended 2021 Equity Incentive Plan approved (20,146,430 for, 6,767,428 against, 4,036 abstain).
- Plan amendment expands evergreen provision to include pre-funded warrants in share reserve calculation and adds automatic full vesting of time-based awards upon employee death.
- Ratification of Ernst & Young as independent auditor for FY 2026 passed (33,877,004 for, 133,499 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/0001193125-26-269431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312526269431/vor-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-269431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer